This Is Not The Medical Marijuana Stock That You Want

I like the risk-reward situation here, at a market cap under $700 million, than I did when the company was over $1.2 billion, but only for an investor that’s willing to hold for multiple years. In this biotech market, it’s hard to say whether GW Pharmaceuticals has hit bottom, especially since it’s trading considerably... more →
Posted in: Investing, News, Stocks

Stocks That Could Go Up In Smoke Are Marijuana Penny Stocks

For example, I like Insys because it already markets Subsys, a sublingual opiate spray that saw its sales grow 105% year over year to $58 million in the third quarter. Thanks to Subsys, the company is debt free and has plenty of financial firepower to pursue pipeline opportunities without diluting investors. In my view, that suggests... more →
Posted in: Investing

Marijuana Could Fight Or Potentially Cure These 5 Diseases

The costs to treat schizophrenia range from $32.5 billion to $65 billion annually.  In 2012, a study published in Translational Psychiatry hinted that cannabinoid CBD may prove to be an attractive substitute for current antipsychotic treatments. In total, the study examined 39 patients, dosing 20 with CBD and 19 with amisulpride. While... more →
Posted in: Investing

You Should Be Aware Of Marijuana Stocks

Douglass: Yes, and when you look at that revenue differential — again, just quoting Yahoo! Finance — GW Pharma‘s is under $50 million for the trailing 12 months, and Insys’ is right around $200 million, so you have the same valuation on 4x the sales. Okay, that may be a better opportunity for folks. You can... more →
Posted in: Investing

Are These Marijuana Stocks Included In Your Winning Portfolio?

The market for legalized marijuana will grow by 64% between 2014 and 2015, cites State of Marijuana Markets, “Cannabis is one of the fastest-growing industries,” Steve Berg tells The Huffington Post, “domestically, we weren’t able to find any market that is growing as quickly.” The legal marijuana industry... more →
Posted in: Investing

Information From NASDAQ Regarding Marijuana Stocks 2015

I guess my people will call your people. We’ll make sure that happens more in the future, all right? All right, sounds good. One of the things that biotech investors, health care investors — heck, general retail investors — are really interested in is marijuana stocks, particularly because we’ve got some... more →
Posted in: Investing

Marijuana’s Promise Of Profit Remains Difficult To Find For The Meantime

Regardless, investors should gain additional insight into Sativex’s efficacy in cancer pain soon. The first of three phase 3 trials for the indication is wrapping up this month, and that has GW Pharma telling investors that it will report data from the trial early next year. A second trial should offer up results before the... more →
Posted in: Investing

There’s Profit In Marijuana But Remains Elusive For The Meantime

Regardless, investors should gain additional insight into Sativex’s efficacy in cancer pain soon. The first of three phase 3 trials for the indication is wrapping up this month, and that has GW Pharma telling investors that it will report data from the trial early next year. A second trial should offer up results before the... more →
Posted in: Investing

Marijuana Stock GW Pharmaceuticals Could Fall And There Are 3 Reasons Why, According To NASDAQ

That’s not to say that GW Pharma won’t be the exception, but it does cast some doubt on whether the valuation being given to the company’s shares is justified. After all, GW Pharma’s current market cap of $1 billion is about 20 times its annualized trailing-quarter sales. For comparison, when Amgen paid 17... more →
Posted in: Investing

The Market’s Idea About This Popular Pot Stock Is Wrong

Developing innovative therapies to treat important diseases takes drug developers down many paths, and patients, doctors, and investors should be glad to know companies like GW Pharma are doing solid work to find new treatments for complex diseases. But that doesn’t mean investors should dive in at any price. Patients are already... more →
Posted in: News
1 2